YOU ARE HERE: LAT HomeCollectionsHuman Immuno Deficiency Virus

Human Immuno Deficiency Virus

July 24, 2007 | From Times Wire Services
Five Bulgarian nurses and a Palestinian doctor sentenced to life in prison in Libya for allegedly infecting more than 400 children with HIV flew out of Tripoli today with French First Lady Cecilia Sarkozy, France's presidential palace said. Sarkozy's delegation arrived Sunday in Tripoli, Libya's capital, to try to negotiate the release. Its members include the European Union commissioner for foreign affairs, Benita Ferrero-Waldner, and French presidential aide Claude Gueant.
July 14, 2007 | From Times Staff and Wire Reports
Using diaphragms in addition to condoms provides no extra protection against the AIDS virus, researchers reported Friday in the journal Lancet. Researchers gave 5,045 women in South Africa and Zimbabwe an HIV-prevention package that included condoms; some received diaphragms as well. But the incidence of the human immunodeficiency virus that causes AIDS was the same in both groups, around 4%.
July 6, 2007 | Jia-Rui Chong, Times Staff Writer
An experimental AIDS drug taken in combination with a recently approved medication dramatically reduced the amount of virus in the blood of patients with a history of drug resistance, according to two international studies published today. The studies reported that up to 18% more drug-resistant patients saw the amount of virus in their blood drop to undetectable levels after 24 weeks compared with those taking a standard drug regimen.
June 28, 2007 | From Times Wire Reports
A Kazakh court convicted 21 medical workers of having roles in infecting scores of children with HIV. The Shymkent district court gave suspended sentences to five senior health officials, including the district's chief medical officer, according to the ruling by Judge Ziyadinkhan Pirniyaz. Sixteen other medical workers, including nurses and doctors in the city's hospital and clinics, received sentences of up to five years.
June 23, 2007 | From Times Staff and Wire Reports
Pfizer Inc., the world's biggest drug maker, failed to win U.S. approval for maraviroc, the first new type of medicine in a decade to treat HIV, the virus that causes AIDS. Pfizer is working on changes the Food and Drug Administration sought on the product's labeling, the company said Wednesday. Maraviroc is intended for patients who have failed to reduce their levels of HIV with other treatments.
June 23, 2007 | Amber Dance, Times Staff Writer
Humans may lack resistance to HIV in part because a potentially defensive protein is still guarding against a long-extinct virus, scientists reported Friday. Researchers have known that some primates, such as macaques, can fight off HIV with an antiviral protein called TRIM5-alpha, whereas the human version, though only slightly different, cannot combat HIV. Scientists at the Fred Hutchinson Cancer Research Center in Seattle wondered just what virus the human protein was able to attack.
May 31, 2007 | James Gerstenzang, Times Staff Writer
President Bush said Wednesday that he would ask Congress to increase U.S. support for the global fight against HIV/AIDS to $30 billion over five years from the current commitment of $15 billion. The White House estimates the increased spending would treat 2.5 million people, prevent 12 million infections and provide additional care for 12 million people, among them 5 million orphans and other children. In the program's first three years, through March, it helped pay for treatment of 1.
May 9, 2007 | From Times Wire Reports
Former President Clinton announced agreements with drug companies to lower the price of "second-line" AIDS drugs for people in the developing world and to make a once-a-day AIDS pill available for less than $1 a day. The anti-retroviral drugs are needed by patients who develop resistance to first-line treatment and cost 10 times as much as first-line therapy, Clinton said in New York. Nearly half a million will require these drugs by 2010.
April 25, 2007 | From the Associated Press
The federal government should approve a novel drug that targets the cells of HIV-infected patients and not the virus itself, health advisors recommended Tuesday. The 12 advisors unanimously voted to urge the Food and Drug Administration to approve maraviroc, which Pfizer Inc. hopes to sell under the brand name Celsentri. It would represent the first so-called CCR5 receptor antagonist to be sold.
April 21, 2007 | Thomas H. Maugh II, Times Staff Writer
German researchers have found a peptide in human blood that blocks HIV and have identified a synthetic variant that is 100 times more potent, they reported Friday in the journal Cell. The synthetic version has been shown to be safe in animals and the team hopes to begin trials in humans this year, they said.
Los Angeles Times Articles